- Home
- OPHC vs IPA Comparison
OPHC vs IPA Comparison
Compare OPHC & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- IPA
- Stock Information
- Founded
- OPHC 2000
- IPA 1983
- Country
- OPHC United States
- IPA United States
- Employees
- OPHC N/A
- IPA N/A
- Industry
- OPHC Major Banks
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- IPA Health Care
- Exchange
- OPHC Nasdaq
- IPA Nasdaq
- Market Cap
- OPHC 51.8M
- IPA 46.0M
- IPO Year
- OPHC N/A
- IPA 2017
- Fundamental
- Price
- OPHC $4.52
- IPA $1.06
- Analyst Decision
- OPHC
- IPA Strong Buy
- Analyst Count
- OPHC 0
- IPA 2
- Target Price
- OPHC N/A
- IPA $4.00
- AVG Volume (30 Days)
- OPHC 8.2K
- IPA 5.0M
- Earning Date
- OPHC 08-05-2025
- IPA 07-28-2025
- Dividend Yield
- OPHC N/A
- IPA N/A
- EPS Growth
- OPHC 30.24
- IPA N/A
- EPS
- OPHC 1.33
- IPA N/A
- Revenue
- OPHC $39,980,000.00
- IPA $16,581,105.00
- Revenue This Year
- OPHC N/A
- IPA $4.67
- Revenue Next Year
- OPHC N/A
- IPA $14.15
- P/E Ratio
- OPHC $3.37
- IPA N/A
- Revenue Growth
- OPHC 53.28
- IPA 1.34
- 52 Week Low
- OPHC $3.53
- IPA $0.27
- 52 Week High
- OPHC $5.90
- IPA $1.16
- Technical
- Relative Strength Index (RSI)
- OPHC 56.95
- IPA 69.86
- Support Level
- OPHC $4.42
- IPA $1.03
- Resistance Level
- OPHC $4.62
- IPA $1.15
- Average True Range (ATR)
- OPHC 0.06
- IPA 0.15
- MACD
- OPHC 0.01
- IPA 0.01
- Stochastic Oscillator
- OPHC 61.54
- IPA 79.96
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.